Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma.
This paper reports the experience of a single investigator team on the use of autografting in support of myeloablative therapy for multiple myeloma. This demonstrates continued progress toward decreased morbidity, and virtual elimination of mortality, as a result of rapid hematopoietic recovery, due to the use of peripheral blood stem cell grafts in newly diagnosed patients receiving several non-cross-resistant induction regimens followed by two autologous transplants, complete remission rates in excess of 50% can be achieved. Prognostic factors have also been identified for event-free and overall survival.
Barlogie
B
B
Division of Hematology-Oncology, University of Arkansas for Medical Sciences, Little Rock 72205.
Jagannath
S
S
Vesole
D
D
Tricot
G
G
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006133:Growth Substances / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D011379:Prognosis; D014182:Transplantation, Autologous
D000900:Anti-Bacterial Agents; D006133:Growth Substances; D016756:Immunoglobulins, Intravenous; D008558:Melphalan